Jon Faldasz: Ondansetron May Have Cardiotoxicity Risk Among 5-HT3RAs Due to High Concentration in Cardiac Tissues
Jon Faldasz, Senior Director of Product and Customer Experience at InsightRX, posted on LinkedIn:
”Just dropped: Ondansetron may have outstanding cardiotoxicity risk among 5-HT3RAs due to high concentration in cardiac tissues
Published today in Nature Scientific Reports, Cai et al used the FDA’s Adverse Event Reporting System (FAERS) to review records of cardiotoxicity associated with 5-HT3RA use. They found:
– The different 5-HT3RAs exhibit varying degrees and types of cardiotoxicity
– QT prolongation was most common for ondansetron (granisetron was least common)
– In a subsequent PBPK model extrapolation they estimated that ondansetron concentrations in cardiac tissue were 2.3x higher than plasma.
They suggested that providers might “prioritize low cardiac toxicity 5-HT3RAs” (read: avoid ondansetron) in patients with heart disease.
For my part, FAERS seems like an untapped resource for this type of work, now I’m thinking on what other investigations could make use of it.
Article reference here.”
Title: Cardiotoxicity of different 5-HT3 receptor antagonists analyzed using the FAERS database and pharmacokinetic study
Authors: Yijun Cai, Shaohong Luo, Shen Lin, Xiaoting Huang, Xiangzhen Wang, Lijing Yang, Xiongwei Xu, Xiuhua Weng

Stay updated with Hemostasis Today.
-
Aug 26, 2026, 15:48Melissa Hollo: Postpartum Depression is More Than the “Baby Blues”
-
Aug 26, 2026, 15:46Raghavendra Rao: The Link Between Neuropathy and Chronic Venous Disease
-
Aug 26, 2026, 15:43Laurent Bertoletti: Long Term Benefits and Safety of Rehabilitation in Pulmonary Arterial Hypertension
-
Aug 26, 2026, 15:41Tamer Hellou: Chromosome 1q Gain Signals High Long-Term Risk in AL Amyloidosis
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal
-
Aug 26, 2026, 14:46Holly O’Byrne: A Framework for Developing and Managing Prehospital Blood Programs
-
Aug 26, 2026, 14:32Eleftherios Mylonakis: Earlier Intervention, Better Risk Stratification, Stronger BP Control
-
Aug 26, 2026, 14:32Bringing ISTH 2026 Research to the Global Scientific Community
-
Aug 26, 2026, 14:23Joseph R. Shaw: Thrombin Generation and the Pharmacodynamics of Oral Anticoagulants